Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

This article (1) has been retracted at the request of the editors. The AACR Publications Department was notified that the U.S. Department of Health and Human Services’ Office of Research Integrity (ORI) determined that G. Dasmahapatra, the first author of the above-mentioned article, engaged in research misconduct by falsifying and/or fabricating data that appeared in the 2011 article (2). The ORI findings report that “the respondent falsified and/or fabricated data by reporting the results of Western blot experiments and mouse imaging experiments that examined interactions between multiple histone deacetylase and/or proteasome inhibitors in several cancer models. Specifically, respondent reused, and/or relabeled Western blot panels and mouse images and claimed they represented different controls and/or experimental results in: Figs. 2B, 3D (Tubulin), and 6B (0 day—CFZ-2.0 mg/Kg and 12 day—CFZ + VOR)” (2). The matter was reviewed by members of the AACR Publications staff and the MCT editors, who agree that the figure manipulation present in the article merits retraction.

A copy of this Retraction Notice was sent to the last known email addresses for all 8 of the authors. 5 authors (E. Attkisson, P. Dent, R.I. Fisher, J.W. Friedberg, and S. Grant) agreed to the retraction; 2 authors (D. Lembersky and M.P. Son) did not respond; and the 1 author (G. Dasmahapatra) could not be located.